DBV Technologies(US:DBVT) Globenewswire·2025-05-05 20:30Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [3][4] - The company is headquartered in Châtillon, France, with North American operations in Warren, NJ [4] Technology and Treatment Approach - DBV Technologies is investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by hypersensitive immune reactions [3] - The VIASKIN® patch is designed to introduce microgram amounts of biologically active compounds to the immune system through intact skin, utilizing epicutaneous immunotherapy (EPIT™) [3] - EPIT™ aims to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergens, leveraging the skin's immune tolerizing properties [3] Clinical Trials and Focus Areas - The company is currently conducting ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (ages 1 to 3) and children (ages 4 to 7) [3]